Absci To Participate In The 43Rd Annual J.P. Morgan Healthcare Conference
(MENAFN- GlobeNewsWire - Nasdaq) VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare conference in San Francisco, CA.
Absci management is scheduled to present on Wednesday, January 15th at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company's investor relations website at: investors.absci.com.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creatio TM platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci ), X (Twitter) (@Abscibio ), and YouTub .
Investor Contact
Alex Khan
VP, Finance & Investor Relations
...
Media Contact
...
MENAFN02012025004107003653ID1109049222
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.